Next generation predictive biomarkers for immune checkpoint inhibition.
about
Familial Lung Cancer: A Brief History from the Earliest Work to the Most Recent StudiesPrecision medicine driven by cancer systems biology.Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma.Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego MooresHigh expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations.Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease.Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns.Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy.Potential role of radiation therapy in augmenting the activity of immunotherapy for gynecologic cancers.Comparison of immune microenvironments between primary tumors and brain metastases in patients with breast cancer.The RA-MAP Consortium: a working model for academia-industry collaboration.Challenging Standard-of-Care Paradigms in the Precision Oncology Era.Immunotherapy in Gastrointestinal Cancers.The Protein Expression of PDL1 Is Highly Correlated with Those of eIF2 and ATF4 in Lung CancerEfficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysisRationale for an Association Between PD1 Checkpoint Inhibition and Therapeutic Vaccination Against HIV
P2860
Q29248944-3E335B09-6588-4F73-9DBE-136BD102F2E9Q37742635-DECDA17B-DC02-4035-9868-D7D601C7D0D4Q38611235-EB730B68-5442-4CCF-8044-D9E4E91FC196Q38759531-A6D7F9CE-F3CB-4872-BF58-541F36738CCCQ38760780-F3D43D2A-8123-446D-95B5-D36D6A2624CAQ38839124-32FB9A53-3266-4DD1-B92A-48565F1F98ADQ42352191-9D3B42E4-FC62-4CF7-8DB6-5983C054CBA2Q44209463-497D261E-2182-434F-AC00-605742ED6B7DQ46685856-DF653C71-DC03-4D84-BC06-F04C80E619DCQ46708524-DB4B79C4-EC96-4FE9-AA29-AE6B325C3145Q47162071-58763ACA-F4B5-4AE6-B2CE-10BDD0C9DF8AQ47355032-C5C5B0EA-2842-4462-8396-ED19C238D74CQ49835188-D31C8517-42AA-4B3C-B3D4-1CBD97E983E4Q53183990-E61ED05F-AF74-4716-A7B9-5C7EB2ED63CAQ57300289-7FBF89DF-65C8-4DFE-807C-5F6EBF6BFB11Q58756789-12918FE1-C7CA-4705-BAC6-BAA15D8BF91EQ59127693-9ADEB6DD-F070-4375-9EB4-B757754FC5A2
P2860
Next generation predictive biomarkers for immune checkpoint inhibition.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Next generation predictive biomarkers for immune checkpoint inhibition.
@en
Next generation predictive biomarkers for immune checkpoint inhibition.
@nl
type
label
Next generation predictive biomarkers for immune checkpoint inhibition.
@en
Next generation predictive biomarkers for immune checkpoint inhibition.
@nl
prefLabel
Next generation predictive biomarkers for immune checkpoint inhibition.
@en
Next generation predictive biomarkers for immune checkpoint inhibition.
@nl
P2860
P1476
Next generation predictive biomarkers for immune checkpoint inhibition.
@en
P2093
Sandip Pravin Patel
Yulian Khagi
P2860
P2888
P304
P356
10.1007/S10555-016-9652-Y
P577
2016-11-21T00:00:00Z